Literature DB >> 33302525

Identifying Ovarian Cancer in Symptomatic Women: A Systematic Review of Clinical Tools.

Garth Funston1, Victoria Hardy1, Gary Abel2, Emma J Crosbie3,4, Jon Emery1,5, Willie Hamilton2, Fiona M Walter1,5.   

Abstract

In the absence of effective ovarian cancer screening programs, most women are diagnosed following the onset of symptoms. Symptom-based tools, including symptom checklists and risk prediction models, have been developed to aid detection. The aim of this systematic review was to identify and compare the diagnostic performance of these tools. We searched MEDLINE, EMBASE and Cochrane CENTRAL, without language restriction, for relevant studies published between 1 January 2000 and 3 March 2020. We identified 1625 unique records and included 16 studies, evaluating 21 distinct tools in a range of settings. Fourteen tools included only symptoms; seven also included risk factors or blood tests. Four tools were externally validated-the Goff Symptom Index (sensitivity: 56.9-83.3%; specificity: 48.3-98.9%), a modified Goff Symptom Index (sensitivity: 71.6%; specificity: 88.5%), the Society of Gynaecologic Oncologists consensus criteria (sensitivity: 65.3-71.5%; specificity: 82.9-93.9%) and the QCancer Ovarian model (10% risk threshold-sensitivity: 64.1%; specificity: 90.1%). Study heterogeneity precluded meta-analysis. Given the moderate accuracy of several tools on external validation, they could be of use in helping to select women for ovarian cancer investigations. However, further research is needed to assess the impact of these tools on the timely detection of ovarian cancer and on patient survival.

Entities:  

Keywords:  diagnostic prediction model; early detection; ovarian cancer; ovarian cancer symptoms; risk assessment; symptoms; triage tool

Year:  2020        PMID: 33302525      PMCID: PMC7764009          DOI: 10.3390/cancers12123686

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  39 in total

1.  Diagnostic test for ovarian cancer composed of ovarian cancer symptom index, menopausal status and ovarian cancer antigen CA125.

Authors:  R Macuks; I Baidekalna; S Donina
Journal:  Eur J Gynaecol Oncol       Date:  2011       Impact factor: 0.196

2.  Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Authors:  Saundra S Buys; Edward Partridge; Mark H Greene; Philip C Prorok; Douglas Reding; Thomas L Riley; Patricia Hartge; Richard M Fagerstrom; Lawrence R Ragard; David Chia; Grant Izmirlian; Mona Fouad; Christine C Johnson; John K Gohagan
Journal:  Am J Obstet Gynecol       Date:  2005-11       Impact factor: 8.661

3.  Development of an ovarian cancer symptom index: possibilities for earlier detection.

Authors:  Barbara A Goff; Lynn S Mandel; Charles W Drescher; Nicole Urban; Shirley Gough; Kristi M Schurman; Joshua Patras; Barry S Mahony; M Robyn Andersen
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

4.  Pathways to the diagnosis of ovarian cancer in the UK: a cohort study in primary care.

Authors:  J Barrett; D J Sharp; S Stapley; C Stabb; W Hamilton
Journal:  BJOG       Date:  2010-01-29       Impact factor: 6.531

5.  Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Authors:  Paul F Pinsky; Kelly Yu; Barnett S Kramer; Amanda Black; Saundra S Buys; Edward Partridge; John Gohagan; Christine D Berg; Philip C Prorok
Journal:  Gynecol Oncol       Date:  2016-09-09       Impact factor: 5.482

6.  Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.

Authors:  Barbara A Goff; Lynn S Mandel; Cindy H Melancon; Howard G Muntz
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

Authors:  Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

9.  Implementing a QCancer risk tool into general practice consultations: an exploratory study using simulated consultations with Australian general practitioners.

Authors:  P P-C Chiang; D Glance; J Walker; F M Walter; J D Emery
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

10.  Risk of ovarian cancer in women with symptoms in primary care: population based case-control study.

Authors:  William Hamilton; Tim J Peters; Clare Bankhead; Deborah Sharp
Journal:  BMJ       Date:  2009-08-25
View more
  6 in total

1.  Modified HE4, CA125, and ROMA cut-off values and predicted probability of ovarian tumor in Chinese patients.

Authors:  Xingping Zhao; Meidan Zhao; Bingsi Gao; Aiqian Zhang; Dabao Xu
Journal:  Gland Surg       Date:  2021-11

2.  Overexpression of NPTX2 Promotes Malignant Phenotype of Epithelial Ovarian Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia.

Authors:  Xiaotian Han; Yechen Lu; Xiaoqi Li; Lingfang Xia; Hao Wen; Zheng Feng; Xingzhu Ju; Xiaojun Chen; Xiaohua Wu
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

3.  Risk prediction models for symptomatic patients with bladder and kidney cancer: a systematic review.

Authors:  Hannah Harrison; Juliet A Usher-Smith; Lanxin Li; Lydia Roberts; Zhiyuan Lin; Rachel E Thompson; Sabrina H Rossi; Grant D Stewart; Fiona M Walter; Simon Griffin; Yin Zhou
Journal:  Br J Gen Pract       Date:  2021-12-31       Impact factor: 5.386

4.  Early diagnosis of symptomatic ovarian cancer in primary care in the UK: opportunities and challenges.

Authors:  Sanketh Rampes; Shern-Ping Choy
Journal:  Prim Health Care Res Dev       Date:  2022-09-02       Impact factor: 1.792

5.  Special Issue "Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer".

Authors:  Ranjit Manchanda
Journal:  Cancers (Basel)       Date:  2022-01-10       Impact factor: 6.639

6.  Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.

Authors:  Jiewen Wang; Guangbo Kang; Haibin Yuan; Xiaocang Cao; He Huang; Ario de Marco
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.